Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment

The document reviewed the dermatologic adverse effects of new targeted small-molecule oral cancer therapies approved by the FDA between 2013 and 2018. It found that while these agents are generally less toxic than traditional chemotherapy, they can cause skin-related side effects such as rashes, palmar-plantar dysesthesia, alopecia, secondary skin malignancies, and changes to hair and nails. Severe reactions like Stevens-Johnson Syndrome and toxic epidermal necrolysis are rare. The literature often lacks specific management strategies for these toxicities, but recommendations include skin monitoring, prophylactic management for palmar-plantar dysesthesia, and the use of corticosteroids or antihistamines. Dose interruption may also be necessary. The authors emphasize the importance of patient education and timely intervention to optimize treatment.